Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  

23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
2014-002281-70: Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted darunavir (the AdvanZ-4 Trial). Reconstitución inmune en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3 que reciben un régimen de fármacos antirretrovirales basado en dolutegravir o darunavir/ritonavir. Estudio AdvanZ-4.

Ongoing
4
108
Europe
CoatedTablet600 mg de abacavir ( sulfate) 300 mg de lamivudine, PREZISTA 300 mg comprimidos recubiertos con película darunavir, Norvir 100 mg soft tablets, Triumeq, Coated tablet, Capsule, soft, Tablet, KIVEXA( Abacavir 600 mg/ Lamivudine 300 mg) recovered tablets, PREZISTA 300 mg recovered Tablets, NORVIR 100 mg soft Tablets, TRIUMEQ®: Lamivudine(3TC) 300 mg+ Abacavir(ABC) 600 mg + dolutegravir(DGT) 50 mg : 1 comprimido
Fundació Clínic per a la Recerca Biomèdica, ViiV Healthcare UK Limited 980 Great West Road Brentford Middlesex TW8 9GS Reino Unido
tratement HIV infection tratamiento de la infección por HIV, HIV infection infección por HIV, Diseases [C] - Virus Diseases [C02]
 
 
2015-000274-35: clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression. ENSAYO CLÍNICO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD Y EFICACIA DE DOS ESTRATEGIAS DE SIMPLIFICACIÓN BASADAS EN DOLUTEGRAVIR EN PACIENTES INFECTADOS POR VIH CON SUPRESIÓN VIROLÓGICA SOSTENIDA.

Ongoing
4
450
Europe
Lamivudine, Efavirenz, nevirapine, J05AX12, Coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Tivicay, Stribild, TRUVADA, KIVEXA, ZIAGEN, VIREAD, EMTRIVA, ATRIPLA, EVIPLERA, ISENTRESS, RAYATAZ, PREZISTA, KALETRA, NORVIR, INTELENCE, EDURANT, TRIUMEQ
Fundació Lluita contra la SIDA, Fundació Lluita contra la SIDA
Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH)., HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
2015-005297-37: Bone Evaluation in women over 40 who Switch from Truvada/NNRTI to Triumeq

Ongoing
4
90
Europe
Tenofovir, Lamivudine, Efavirenz, Nevirapine, Etravirine, Rilpivirine, Film-coated tablet, Tablet, Triumeq, Truvada, Atripla, Eviplera
King's College Hospital NHS Foundation Trust, ViiV Healthcare Ltd
Human Immunodeficiency Virus, People infected with Human Immunodeficiency Virus (HIV), Diseases [C] - Immune System Diseases [C20]
 
 
2016-004646-29: DREAM study Estudio DREAM

Ongoing
4
64
Europe
Triumeq, Genvoya, Tablet, Triumeq, Genvoya
Fundación SEIMC-GESIDA, GILEAD Sciencies S.A.
HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02]
 
 
2017-000469-62: Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients. DGT-SOT Ensayo clínico piloto de un brazo para evaluar la eficacia, las interacciones farmacocinéticas y la seguridad del dolutegravir más 2 inhibidores nucleósidos de la Transcriptasa Inversa (NRTIs en su siglas en inglés) en pacientes trasplantados de órganos sólidos infectados por el VIH-1. DGT-SOT

Ongoing
4
20
Europe
Triumeq 50 mg/600 mg/300 mg comprimidos recubiertos con película dolutegravir/abacavir/lamivudina, Tivicay 50 mg, Truvada comprimidos recubiertos con película., Coated tablet, Tablet, Triumeq®, Dolutegravir 50 mg, 200 mg de emtricitabina y 245 mg de tenofovir disoproxil (equivalente a 300 mg de tenofovir disoproxil fumarato ó 136 mg de tenofovir).
Fundació Clínic per a la Recerca Biomèdica, ViiV Healthcare
HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., Diseases [C] - Virus Diseases [C02]
 
 
2018-001645-14: Study to compare two treatments in patients who have never taken HIV medication randomized in different centers in Spain. (The Symtri study) Estudio para comparar dos tratamientos en pacientes que nunca han tomado medicación para el VIH asignados al azar realizado en diferentes centros de España. (Estudio SYMTRI)

Ongoing
4
316
Europe
Film-coated tablet, Symtuza, Triumeq
Spanish HIV/AIDS Research Networkº, Spanish HIV/AIDS Research Network
HIV infection Infección por VIH, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos.

Ongoing
4
100
Europe
lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy
FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare
HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
2018-001158-82: DETOX Study Estudio DETOX

Ongoing
4
110
Europe
Symtuza, Tablet, Symtuza, Triumeq
Fundación SEIMC-GESIDA, JANSSEN CILAG S.A
HIV VIH, HIV VIH, Diseases [C] - Virus Diseases [C02]
 
 
2019-004007-12: BIC CNS Study

Not yet recruiting
4
46
Europe
Biktarvy, Triumeq, Film-coated tablet, Biktarvy, Triumeq
University of Sussex, Gilead Sciences
HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
2019-004620-38: Study to see the changes in body weight and body composition of a darunavir/cobicistat based treatment in HIV-infected people who have gained weight during a dolutegravir-based treatment. Estudio para ver los cambios en el peso y la composición del cuerpo de un tratamiento basado en darunavir/cobicistat en personas con infección por el VIH que han aumentado de peso durante un tratamiento basado en dolutegravir.

Not yet recruiting
4
60
Europe
Triumeq, Rezolsta, Kivexa, Symtuza, Film-coated tablet, Triumeq, Rezolsta, Kivexa, Symtuza
Fundació Lluita contra la SIDA, Fundació Lluita contra la SIDA
HIV infection Infección por el VIH, HIV infection Infección por el VIH, Diseases [C] - Immune System Diseases [C20]
 
 
2016-000087-42: Triumeq As an Integrase Single Tablet Regimen in People with HIV who Inject Drugs

Not yet recruiting
4
50
Europe
Triumeq, Film-coated tablet, Triumeq
University College Dublin, ViiV Healthcare
Human Immunodeficiency Virus (HIV) infection, HIV infection, Diseases [C] - Immune System Diseases [C20]
 
 
AVERTAS-1, NCT04904406: Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

Completed
4
81
Europe
Dolutegravir / Lamivudine Oral Tablet, Dolutegravir/abacavir/lamivudine
Thomas Benfield
Hiv, HIV Infections, HIV Cardiomyopathy, Weight Change, Body, HIV Lipodystrophy, Cardiovascular Diseases
12/23
12/23
2019-004999-19: Changes in weight, body composition and metabolic parameters in HIV infected patients after switched treatment

Not yet recruiting
4
95
Europe
Tablet, Triumeq, Dovato
Department of infectious diseases, Hvidovre Hospital, The Simonsen’s Foundation
Human immunodeficiency viruses (HIV), Human immunodeficiency viruses (HIV), Diseases [C] - Virus Diseases [C02]
 
 
Moso, NCT05393193: Point-of-Care HIV Testing and Early Dolutegravir Use for Infants

Recruiting
4
900
RoW
Point-of-Care Cepheid Xpert HIV-1, DTG/ABC/3TC
Harvard School of Public Health (HSPH), Botswana Harvard AIDS Institute Partnership, Ragon Institute of MGH, MIT and Harvard, Botswana Ministry of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
HIV
05/26
08/26
NCT02131025: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

Active, not recruiting
3
428
US, Canada
ABC/DTG/3TC FDC, Ongoing cART regimen
ViiV Healthcare, PPD, GlaxoSmithKline
Infection, Human Immunodeficiency Virus
04/15
10/15
FLAIR, NCT02938520 / 2016-001646-25: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Active, not recruiting
3
631
Europe, Canada, Japan, US, RoW
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet
ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline
HIV Infections
08/18
12/26
2018-004885-32: THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR (D/L/A) TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) IN PATIENTS WITH SUPPRESSED VIRAL LOAD ON NEUROPSYCHIATRIC SIDE EFFECTS AND NEUROCOGNITIVE FUNCTION L’IMPATTO DEL PASSAGGIO DA DOLUTEGRAVIR/LAMIVUDINA/ABACAVIR (D/L/A) A BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE (B/F/TAF) NEI PAZIENTI IN TERAPIA ANTIRETROVIRALE CON HIVRNA SOPPRESSO SUGLI EVENTI AVVERSI NEUROPSICHIATRICI E SULLE FUNZIONI NEUROCOGNITIVE

Not yet recruiting
3
100
Europe
bictegravir/emtricitabina/tenofovir alafenamide, TRIUMEQ, [GS-9883-01], [dolutegravir/abacavir/lamivudina], Tablet, BIKTARVY, TRIUMEQ
AZIENDA OSPEDALIERA UNIVERSITARIA SENESE, Gilead Sciences
HIV-1 infection Infezione da HIV-1, Human immunodeficiency virus type 1 (HIV-1) infection Infezione da virus dell'immunodeficienza umana acquisita 1 (HIV-1), Diseases [C] - Virus Diseases [C02]
 
 
2020-005069-15: LIGHTHOUSE 2

Not yet recruiting
3
390
Europe
Triumeq, Capsule, Triumeq
Stichting TRICALS Foundation, ALS Stichting Nederland., Fight MND, Ulla-Carin Lindquist Foundation, Luzon Foundation, Research Motor Neurone
Amyotrophic Lateral Sclerosis (ALS), ALS/ Motor Neuron Disease (MND), Diseases [C] - Nervous System Diseases [C10]
 
 
2022-001437-36: ITACO study and the Analytical Antiretroviral Treatment Interruption study (ITACO-ATI) Studio ITACO e studio sull'interruzione del Trattamento Antiretrovirale (ITACO-ATI)

Not yet recruiting
3
61
Europe
ODEFSEY, REZOLSTA, BIKTARVY, Triumeq, Edurant, Tivicay, Descovy, Symtuza, Dovato, Epivir, [na], Film-coated tablet, ODEFSEY - 200 MG/25 MG/25 MG- COMPRESSA RIVESTITA- USO ORALE- FLACONE (HDPE) 30 COMPRESSE, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, Biktarvy, TRIUMEQ - 50MG/600MG/300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE HDPE - 1 FLACONE 30 COMPRESSE, EDURANT - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 30 COMPRESSE, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, DESCOVY - 200 MG/10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, Symtuza, DOVATO - 50 MG / 300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EPIVIR - 300 MG 1 FLACONE 30 COMPRESSE RIVESTITE CON FILM USO ORALE
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA, NIH (Johns Hopkins University)
perinatally HIV infection Infezione da HIV perinatale, perinatally HIV infection Infezione da HIV perinatale, Diseases [C] - Immune System Diseases [C20]
 
 
2020-001426-57: A study to compare whether giving two rather than three anti-HIV medicines daily to children and young people, aged between 2 and 15 years is assafe and effective in controlling their HIV infection Ensayo para comparar si la administración de dos en vez de tres fármacos anti-VIH diariamente en niños y pacientes jóvenes entre 2 y 15 años es tan segura y efectiva en el control de su infección por VIH.

Not yet recruiting
3
370
Europe
DTG/3TC DT, Dovato, Tivicay PD, Tivicay, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy, Dolutegravir, Dispersible tablet, Film-coated tablet, Capsule, hard, Dovato, TIVICAY PD, TIVICAY, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy
Fondazione Penta Onlus, ViiV Healthcare UK Limited
HIV Infection Infección por VIH, HIV Infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
NCT03016533: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Active, not recruiting
3
101
US, RoW
Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets
ViiV Healthcare
HIV Infections
11/24
11/24
Lighthouse III, NCT06658977: RolloverTreatment with Triumeq for People with ALS Following the Lighthouse II Trial

Not yet recruiting
3
70
RoW
Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
Macquarie University, Australia
Amyotrophic Lateral Sclerosis, ALS
12/26
12/26
LIGHTHOUSE II, NCT05193994: Triumeq in Amyotrophic Lateral Sclerosis

Active, not recruiting
3
390
Europe, RoW
Dolutegravir, Abacavir and Lamivudine, Triumeq, Placebo
Macquarie University, Australia, King's College London, Stichting TRICALS Foundation
Amyotrophic Lateral Sclerosis
08/26
08/26

Download Options